PTCT
PTC Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$69.30
−2.94%Aug 28, 2026, 20:21 UTC
PTC Therapeutics agreed to acquire from Sangamo Therapeutics all rights to ST-920, an AAV gene therapy product candidate for Fabry disease, for an upfront payment of $111 million plus up to $100 million in contingent milestone payments.
Aug 12, 2026, 20:01 UTC
PTC Therapeutics announced a planned acquisition of Sangamo Therapeutics' BLA-stage ST-920 Fabry disease gene therapy program, leveraging existing regulatory and commercial infrastructure.
Jul 30, 2026, 22:26 UTC
PTC Therapeutics reported Q2 2026 earnings of $0.92 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share, compared to a loss of $0.83 per share a year ago.
Source:Jun 16, 2026, 03:14 UTC
PTC Therapeutics priced $500 million of 0% Convertible Senior Notes due 2031 to refinance its 2026 convertible notes.
Source: